Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

2.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.9K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

69.7K
Overview
69.7K
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

476
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
476

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute requirement for the hippocampus in putatively conscious vision revealed by a mouse model of blindsight.

Current biology : CB·2026
Same author

CD4<sup>+</sup> Th Cell-Derived Extracellular Vesicles Orchestrate CD8<sup>+</sup> T Cells and Eosinophils to Enhance Anti-Tumor Immunity.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Acute requirement for the hippocampus in putatively conscious vision revealed by a mouse model of blindsight.

Current biology : CB·2026
Same author

Research progress and future prospects of cellulose-based composite gas separation membranes from a green sustainability perspective.

Carbohydrate polymers·2026
Same author

Advantages and Research Progress of Polycarbonates in Flexible Electronic Devices.

Macromolecular rapid communications·2025
Same author

Bioengineering Platelets Presenting PD-L1, Galectin-9 and BTLA to Ameliorate Type 1 Diabetes.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025

Related Experiment Video

Updated: Aug 20, 2025

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

1.9K

Leverage biomaterials to modulate immunity for type 1 diabetes.

Zhangyan Jing1, Yuan Li1, Yumeng Ma1

  • 1Department of Pharmacology, School of Medicine, Shenzhen Campus of Sun Yat-sen University, Sun Yat-sen University, Shenzhen, Guangdong, China.

Frontiers in Immunology
|November 21, 2022
PubMed
Summary

Biomaterials offer a targeted approach to modulate the immune system, protecting insulin-producing beta cells from autoimmune attack in type 1 diabetes (T1D). This strategy aims to reduce side effects associated with broad immunosuppression for T1D treatment.

Keywords:
biomaterialimmune checkpointimmune modulationtype 1 diabetesvaccine

More Related Videos

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
11:31

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

8.0K
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

5.9K

Related Experiment Videos

Last Updated: Aug 20, 2025

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

1.9K
High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
11:31

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

8.0K
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

5.9K

Area of Science:

  • Immunology
  • Biomaterials Science
  • Endocrinology

Background:

  • Type 1 diabetes (T1D) involves autoimmune destruction of pancreatic beta cells, leading to insulin deficiency and hyperglycemia.
  • Current treatments often rely on systemic immunosuppression, which carries significant risks like infection and cancer.
  • Targeted immunomodulation is crucial for preserving residual beta cells and mitigating treatment-related toxicity.

Purpose of the Study:

  • To review recent advancements in utilizing biomaterials for targeted immunomodulation in type 1 diabetes.
  • To explore how biomaterials can enhance the delivery of immunosuppressants and regulate autoimmune responses.
  • To discuss the potential of biomaterials in developing vaccines and promoting immune tolerance for T1D.

Main Methods:

  • Review of current literature on biomaterial applications in T1D immunomodulation.
  • Investigation of nanotechnology for targeted immunosuppressant delivery.
  • Analysis of biological macromolecules for specific T-cell regulation.
  • Exploration of biomaterials in vaccine development and immune tolerance induction.

Main Results:

  • Biomaterials enable targeted delivery of immunosuppressants, minimizing systemic exposure.
  • Specific biomaterial strategies can regulate autoreactive T cells targeting beta cells.
  • Biomaterials show promise in developing vaccines and fostering immunosuppressive cells for pancreatic immune tolerance.

Conclusions:

  • Biomaterials represent a promising strategy for targeted immunomodulation in T1D.
  • Harnessing biomaterials can lead to safer and more effective treatments for new-onset T1D.
  • Further research into biomaterial-based approaches can restore immune tolerance in the pancreas.